{"id":"W2966662961","doi":"10.1200/jco.2012.30.15_suppl.6513","title":"Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dasatinib; Nilotinib; Internal medicine; Adverse effect; Gastroenterology; Imatinib; Neutropenia; Myeloid leukemia; Imatinib mesylate; Pharmacology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003085592,0.000327698,0.0004298099,0.0001984896,0.0002006719,0.0002445359,0.0001316497,0.0003043506,0.0009175254],"category_scores_gemma":[0.0003605419,0.0001305848,0.0002472086,0.0002830504,0.0002088944,0.0002602733,0.0001585697,0.0003780626,0.0001632132],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002551803,"about_ca_system_score_gemma":0.0003534755,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005323521,"about_ca_topic_score_gemma":0.001088303,"domain_scores_codex":[0.9999064,0.00002972675,0.00001013702,0.00001809271,0.00001193472,0.00002369836],"domain_scores_gemma":[0.9998353,0.00003274538,0.00004358402,0.000006224346,0.000005904703,0.00007612766],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1463532,0.006280904,0.4523187,0.001050504,0.0005829406,0.006990342,0.0009446258,0.002504608,0.08133761,0.0002840125,0.005737875,0.2956147],"study_design_scores_gemma":[0.0232567,0.1959663,0.7507486,0.0001359178,0.0003885459,0.008867174,0.0004403081,0.003808574,0.007393633,0.0003107288,0.008645733,0.00003768587],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982105,0.001014257,0.00009349689,0.0001096167,0.00001228064,0.00008087516,0.00007621757,0.000008796059,0.0003940094],"genre_scores_gemma":[0.998991,0.0004444263,0.0001304762,0.0001015879,0.00002777411,0.00003877915,0.0001252941,0.000001051754,0.0001397325],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009175254,"threshold_uncertainty_score":0.003069401,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07884208343562826,"score_gpt":0.4232277760321592,"score_spread":0.344385692596531,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}